Ko Y, Paramsothy S, Yau Y, et al. - In the present study, the researchers sought to assess the persistence of biological agents in Crohn disease (CD) and ulcerative colitis (UC) and the impacts of immunomodulator use and treatment lines. Retrospective national population-based data from the Australian Pharmaceutical Benefits Scheme on treatment persistence for adalimumab, infliximab vedolizumab, and ustekinumab for CD and UC were analyzed using Kaplan-Meier analysis and Cox proportional hazards models. There were 2,499 patients involved with 8219 person-years of follow-up. Ustekinumab in CD and vedolizumab in UC had the highest persistence. First-line therapy and immunomodulator co-therapy in anti-TNF agent use were factors that increased biological agent persistence.